Immune Response to HTLV-I and HTLV-II

摘要: Originally identified from a T-lymphoblastoid cell line (HUT 102) of patient diagnosed with cutaneous T-cell lymphoma, the human T-lymphotropic virus type I (HTLV-I) was first described retrovirus (1). In 1981, HTLV-I established as etiologic agent for adult leukemia (ATL) (2), hematological malignancy characterized in Japan (3). Since initial description ATL and discovery HTLV-I, has been associated an inflammatory, chronic, progressive neurologic disease known myelopathy/tropical spastic paraparesis (HAM/TSP) addition to several other inflammatory diseases (4–14). Although increasing number have linked vast majority HTLV-I—infected individuals remain clinically asymptomatic.